The French government is pressing for guarantees regarding the production and supply of Doliprane, a widely used pain reliever, amid concerns over its potential sale to an American investment fund. Health Minister Geneviève Darrieussecq emphasized the need for Doliprane to be produced in France, ensuring normal supply to pharmacies and maintaining adequate stock levels to prevent shortages. These calls come after Sanofi, the pharmaceutical company that markets Doliprane, announced its intention to sell its consumer health entity Opella to the American firm CD&R.
President Emmanuel Macron has also weighed in on the matter, stating that the government possesses the necessary tools to protect France's interests in the face of this potential sale. Macron highlighted the importance of ensuring that essential medicines, like Doliprane, are produced domestically, reinforcing the government's commitment to maintaining health sovereignty.
